All studies involving C57BL/6J


Filter by:
Data set Procedure What's in this data set Panel Sex Age (weeks) Year
Ackert1 body size and weight Body weight, body length, body mass index. Aging study, 6mo, 12mo, 20mo. inbred   (32) both 26, 52, 87 wks 2008
Ackert1 DXA Body mass, fat mass, lean mass, bone mineral density and content, body area, bone area. Aging study, 6mo, 12mo, 20mo. inbred   (32) both 26, 52, 87 wks 2008
Albers1 lipid profile
with high-fat diet 		Cholesterol, HDL, non-HDL, triglycerides, phospholipids. 4h fast, plasma. Baseline vs. high-fat diet (6wks). inbred   (15) both 6-14wks 1999
Albers1 protein activity assessment
with high-fat diet 		Phospholipid transfer protein activity. 4h fast. inbred   (15) both 6-14wks 1999
Auwerx1 body temperature
with high-fat diet 		In cold room: 0, 1, 2, 3, 4, 5, 6 h. BXD w/par   (57) m 8-29 wks 2016
Auwerx1 body weight
with high-fat diet 		8-29 wks of age. BXD w/par   (57) m 8-29 wks 2016
Auwerx1 cell signaling molecule detection
with high-fat diet 		INF-gamma, interleukins, monocyte chemoattractant, macrophage inflammatory protein, T cell RANTES, TNF-alpha. BXD w/par   (57) m 8-29 wks 2016
Auwerx1 complete blood count
with high-fat diet 		RBC, hematocrit. BXD w/par   (57) m 8-29 wks 2016
Auwerx1 glucose tolerance
with high-fat diet 		Glucose post oral gavage: 0, 15, 30, 45, 60, 90, 120, 150, 180 min plus area under curve. BXD w/par   (57) m 8-29 wks 2016
Auwerx1 hormone quantification
with high-fat diet 		Glucose post oral gavage: 0, 15, 30 min plus area under curve. BXD w/par   (57) m 8-29 wks 2016
Auwerx1 intake monitoring
with high-fat diet 		Food intake. BXD w/par   (57) m 8-29 wks 2016
Auwerx1 lipid profile
with high-fat diet 		Cholesterol, HDL, LDL, free fatty acids, triglyceride. BXD w/par   (57) m 8-29 wks 2016
Auwerx1 metabolic panel
with high-fat diet 		Enzymes, bile acid, proteins, creatinine, glucose, iron, lactate. BXD w/par   (57) m 8-29 wks 2016
Auwerx1 monitoring system
with high-fat diet 		Oxygen consumption and respiratory exchange ratio (RER); activity. BXD w/par   (57) m 8-29 wks 2016
Auwerx1 NMR
with high-fat diet 		Body composition. BXD w/par   (57) m 8-29 wks 2016
Auwerx1 organ weights
with high-fat diet 		Skeletal muscle, soleus muscle, heart, kidney, liver, various fat pads. BXD w/par   (57) m 8-29 wks 2016
Auwerx1 running wheel monitoring
with high-fat diet 		Distance traveled, speed. BXD w/par   (57) m 8-29 wks 2016
Auwerx1 tail cuff
with high-fat diet 		Blood pressure and heart rate. BXD w/par   (57) m 8-29 wks 2016
Auwerx1 treadmill endurance test
with high-fat diet 		Distance traveled. BXD w/par   (57) m 8-29 wks 2016
Auwerx2 body weight
with high-fat diet 		inbred w/CC8 both 8-21 wks 2021
Auwerx2 glucose tolerance
with high-fat diet 		Plasma glucose levels: 0, 15, 30, 45, 60, 90, 120, 150, and 180 min, post oral gavage following overnight fast. inbred w/CC8 both 8-21 wks 2021
Auwerx2 hormone quantification
with high-fat diet 		Insulin levels following glucose post oral gavage: 0, 15, 30 min. inbred w/CC8 both 8-21 wks 2021
Auwerx2 intake monitoring
with high-fat diet 		Food intake. inbred w/CC8 both 8-21 wks 2021
Auwerx2 lipid profile
with high-fat diet 		Cholesterol, HDL, LDL, triglycerides, free fatty acids. inbred w/CC8 both 8-21 wks 2021
Auwerx2 metabolic panel
with high-fat diet 		Enzymes, creatinine, iron, lactate, urea. inbred w/CC8 both 8-21 wks 2021
Auwerx2 monitoring system
with high-fat diet 		Oxygen consumption, carbon dioxide production, respiratory exchange rate (RER); activity. inbred w/CC8 both 8-21 wks 2021
Auwerx2 organ dimensions
with high-fat diet 		Intestine length. inbred w/CC8 both 8-21 wks 2021
Auwerx2 organ weights
with high-fat diet 		Cecum, muscles, heart, heart-atria, kidney, liver, spleen, fat pads. inbred w/CC8 both 8-21 wks 2021
Auwerx2 treadmill endurance test
with high-fat diet 		Distance traveled. inbred w/CC8 both 8-21 wks 2021
Bachmanov1 body weight Body weight inbred   (13) m 7-8wks 2011
Bachmanov1 bottle choice test Sodium chloride solution taste threshold. Fluid intake. inbred   (13) m 7-8wks 2011
Bachmanov1 intake monitoring Water intake. Daily. inbred   (13) m 7-8wks 2011
Benavides1 genotype assessment Gpr84 allele assessment. PCR, sequencing. inbred w/CC8   (58) both 6wks 2013
Benoist1 immune cell quantification Regulatory T cells (Treg), thymus, spleen. inbred   (33) m 5-6wks 2007
Berndt1 ventilator
with methacholine 		Airway resistance. Baseline vs. methacholine-challenged (several doses). inbred   (37) both 9-12wks 2010
Berndt2 plethysmography
with methacholine 		Lung, respiratory function. Baseline vs. methacholine-challenged (several doses). inbred   (29) both 9-12wks 2010
Berndt2 ventilator
with methacholine 		Lung, respiratory function. Anesthetized forced oscillation. Baseline vs. methacholine-challenged (several doses). inbred   (29) both 9-12wks 2010
Berndt3 metabolite quantification Vitamin D concentration (serum). inbred   (18) m 11wks 2011
Berndt4 histopathology Lung adenoma frequency and severity at 20mo. Tumor incidence, cancer, aging. inbred   (28) both 87wks 2011
Bodnar1 intake monitoring
with sucrose 		Food, caloric, water intake. Baseline and with sucrose (several concentrations). 24h test. inbred   (12) m 13-17wks 2006
Bolivar1 open field test Locomotor activity and exploratory behavior. 5 min test in dark. inbred   (10) both 8-14wks 2000
Bolivar2 fear conditioning test Contextual fear, cued fear. inbred   (8) both 9-20wks 2001
Bolivar3 monitoring system Social interaction (study 1 and study 2). inbred   (7) m 8-12wks 2007
Bolivar4 open field test Locomotor activity, exploratory behavior, habituation scores. 15 min test. inbred   (14) m 8-12wks 2009
Boon1 body weight
with influenza A (H5N1) virus 		Influenza A (H5N1) virus (several doses) vs. baseline. inbred   (23) f 6-9wks 2011
Boon1 health assessment
with influenza A (H5N1) virus 		Survival rate, influenza A (H5N1) virus (several doses). Strain H5N1 susceptibility score. inbred   (23) f 6-9wks 2011
Bopp1 health assessment
with Plasmodium berghei 		Susceptibility, Plasmodium berghei (malaria). Parasitemia in blood and distribution in brain, spleen, lungs, liver. inbred   (31) both 8-12wks 2010
Brayton1 study archive Spontaneous diseases. inbred both 2013
Broad2 genotyping SNP profiling, 131,000+ genomic locations, 1-19,X. inbred   (89) 2009
Brown1 body weight Body weight inbred   (14) both 10wks 2004
Brown1 elevated plus maze Locomotor, exploratory, and anxiety-related behavior. inbred   (14) both 10wks 2004
Brown1 elevated zero maze Locomotor, exploratory, and anxiety-related behavior. inbred   (14) both 10wks 2004
Brown1 light-dark box Anxiety, avoidance behavior. inbred   (14) both 10wks 2004
Brown1 open field test Locomotor, exploratory, and anxiety-related behavior. inbred   (14) both 10wks 2004
Brown2 Barnes circular maze Spatial learning and memory. inbred   (14) both 10-18wks 2004
Brown2 Morris water maze Spatial learning and memory. inbred   (14) both 10-18wks 2004
Brown2 olfactory discrimination task Olfactory-related learning and memory. inbred   (14) both 10-18wks 2004
Brown2 rotarod Latency to fall from accelerating rotarod. 7 day trials. inbred   (14) both 10-18wks 2004
Brown2 visual water box Spatial learning and memory. inbred   (14) both 10-18wks 2004
Brugnara1 complete blood count Hematology. inbred   (10) both 8wks 2013
Brugnara1 ion transport assessment Hematology red cell ion content, ion transport. inbred   (10) both 8wks 2013
Bubier3 monitoring system
with morphine 		Induced respiratory depression, time to recovery (for mice that survived), survival data (for mice that did not survive). inbred w/CC8   (8) both 8-24wks 2020
CGD-MDA1 genotyping SNP profiling, 470,000+ genomic locations, 1-19,X,Y,MT. inbred   (142) m 2014
CGD-MDA2 genotyping SNP profiling, 470,000+ genomic locations, 1-19,X,Y,MT. BXD w/par   (92) m 2014
CGD-MDA4 genotyping SNP profiling, 470,000+ genomic locations, 1-19,X,Y,MT. AXB, BXA, BXH, CXB, AKXL w/par   (72) m 2014
CGD-MDA5 genotyping SNP profiling, 470,000+ genomic locations, 1-19,X,Y,MT. B6.A, B6.PWD consomic panels   (53) m 2014
CGDpheno1 body size and weight Body weight and length. inbred w/CC8   (72) both 10-13wks 2009
CGDpheno1 complete blood count Hematology. inbred w/CC8   (72) both 10-13wks 2009
CGDpheno1 DXA Body mass, fat mass, lean mass, bone mineral density. inbred w/CC8   (72) both 10-13wks 2009
CGDpheno1 lipid profile Cholesterol, HDL, triglycerides, free fatty acids. 4h fast, plasma. inbred w/CC8   (72) both 10-13wks 2009
CGDpheno1 metabolic panel Clinical blood chemistry (plasma). 4h fast. inbred w/CC8   (72) both 10-13wks 2009
CGDpheno2 body size and weight Body weight and length, variation over time of controls. one strain: C57BL/6J both 2009
CGDpheno2 complete blood count Hematology. Variation over time of controls. one strain: C57BL/6J both 2009
CGDpheno2 DXA Body mass, fat mass, lean mass, bone mineral density. Variation over time of controls. one strain: C57BL/6J both 2009
CGDpheno2 lipid profile Cholesterol, HDL, triglycerides, free fatty acids. 4h fast, plasma. Variation over time of controls. one strain: C57BL/6J both 2009
CGDpheno2 metabolic panel Clinical blood chemistry (plasma), variation over time of controls. 4h fast. one strain: C57BL/6J both 2009
CGDpheno3 body weight Body weight CC diallel w/par   (62) both 8-16wks 2012
CGDpheno3 complete blood count Hematology. CC diallel w/par   (62) both 8-16wks 2012
CGDpheno3 DXA Body mass, fat mass, lean mass, bone mineral density and content, bone area. CC diallel w/par   (62) both 8-16wks 2012
CGDpheno3 ECG Wave amplitudes and intervals. Conscious. CC diallel w/par   (62) both 8-16wks 2012
CGDpheno3 lipid profile Cholesterol, HDL, triglycerides. 4h fast, plasma. CC diallel w/par   (62) both 8-16wks 2012
CGDpheno3 metabolic panel Glucose (plasma). 4h fast. CC diallel w/par   (62) both 8-16wks 2012
CGDpheno3 tail cuff Heart rate and blood pressure. Conscious mice. CC diallel w/par   (62) both 8-16wks 2012
Chang1 electroretinography Photoreceptor measures: rod Awave, Bwave, cone Bwave. inbred   (17) both 10-13wks 2008
Chang1 organ dimensions Eye diameter. inbred   (17) both 10-13wks 2008
Chang2 ophthalmoscopy Retinal spots, hypopigmentation. B6.PWD consomic w/par   (28) both 44-61wks 2012
Chang2 slit lamp Eye morphology. Frequency rates of disorders. B6.PWD consomic w/par   (28) both 44-61wks 2012
Chen1 immune cell quantification Natural killer T cells in peripheral blood, spleen, thymus. inbred   (38) both 8-10wks 2011
Chesler2 behavior observation Wildness scoring. CC diallel w/par   (62) both 7-15wks 2011
Chesler2 body size and weight Body weight, body length, tail length. CC diallel w/par   (62) both 7-15wks 2011
Chesler2 colony observation Reproduction, fecundity. CC diallel w/par   (62) both 7-15wks 2011
Chesler2 complete blood count Hematology. CC diallel w/par   (62) both 7-15wks 2011
Chesler2 fat pad weights Gonadal fat pad weight. CC diallel w/par   (62) both 7-15wks 2011
Chesler2 light-dark box Anxiety, avoidance behavior. 10 min test. CC diallel w/par   (62) both 7-15wks 2011
Chesler2 metabolic panel Clinical blood chemistry. 16h fast. CC diallel w/par   (62) both 7-15wks 2011
Chesler2 monitoring system Sleep patterns. Dark period, total, peak activity. Baseline and after sleep deprivation. CC diallel w/par   (62) both 7-15wks 2011
Chesler2 nociception assay Hot plate and pressure on tail. CC diallel w/par   (62) both 7-15wks 2011
Chesler2 open field test Locomotor activity, exploratory, anxiety-related behavior. 10 min test. CC diallel w/par   (62) both 7-15wks 2011
Chesler2 organ weights Heart, kidney weights. CC diallel w/par   (62) both 7-15wks 2011
Chesler3 behavior observation Wildness scoring. CC pre w/par   (367) both 7-15wks 2011
Chesler3 body size and weight Body weight, tail length. CC pre w/par   (367) both 7-15wks 2011
Chesler3 bone dimensions Femur. CC pre w/par   (367) both 7-15wks 2011
Chesler3 colony observation Reproduction, fecundity. CC pre w/par   (367) both 7-15wks 2011
Chesler3 complete blood count Hematology. CC pre w/par   (367) both 7-15wks 2011
Chesler3 fat pad weights Gonadal fat pad weights. CC pre w/par   (367) both 7-15wks 2011
Chesler3 light-dark box Anxiety, avoidance behavior. 10 min test. CC pre w/par   (367) both 7-15wks 2011
Chesler3 metabolic panel Clinical blood chemistry. 16h fast. CC pre w/par   (367) both 7-15wks 2011
Chesler3 monitoring system Sleep patterns. Dark period, total, peak activity. Baseline and after sleep deprivation. CC pre w/par   (367) both 7-15wks 2011
Chesler3 nociception assay Hot plate and pressure on tail. CC pre w/par   (367) both 7-15wks 2011
Chesler3 open field test Locomotor activity, exploratory, anxiety-related behavior. 10 min test. CC pre w/par   (367) both 7-15wks 2011
Chesler3 organ dimensions Kidney length and volume. CC pre w/par   (367) both 7-15wks 2011
Chesler3 organ weights Heart, brain, kidney, spleen, gonadal fat pads, testicle weights. CC pre w/par   (367) both 7-15wks 2011
Chesler4 body weight Body weight DO population w/par   (9) both 12-16wks 2013
Chesler4 light-dark box Anxiety, avoidance behavior. 20 min test. DO population w/par   (9) both 12-16wks 2013
Chesler4 nociception assay Hot plate. DO population w/par   (9) both 12-16wks 2013
Chesler4 open field test Locomotor activity, exploratory, anxiety-related behavior. 20 min test. DO population w/par   (9) both 12-16wks 2013
Chesler4 tail suspension test Frequency climbing, time immobile, latency immobile. 5 min test. DO population w/par   (9) both 12-16wks 2013
Chesler4 visual cliff Anxiety, avoidance behavior. 20 min test. DO population w/par   (9) both 12-16wks 2013
Chesler5 study archive Intestinal microbiome study. inbred   (10) both 2012
Churchill1 DXA Body mass, fat mass, lean mass, bone mineral density and content, bone area. F1 8way   (63) both 7-8wks 2004
Churchill1 muscle weights Quadriceps muscle. F1 8way   (63) both 7-8wks 2004
Churchill1 organ dimensions Ear length (pinal). F1 8way   (63) both 7-8wks 2004
Collins1 complete blood count Hematology. CC pre w/par   (139) m 10-14wks 2012
Cowell1 health assessment
with Staphylococcus aureus 		Survival rate, Staphylococcus aureus. inbred   (13) f 8wks 2012
Cowell1 hormone quantification
with Staphylococcus aureus 		Interleukin 6 levels (serum) after infection with Staphylococcus aureus. Kidney and peritoneal fluid. inbred   (13) f 8wks 2012
Cowell1 in vitro assay
with Staphylococcus aureus 		Bacterial load after infection with Staphylococcus aureus. Kidney and peritoneal fluid. In vitro assay. inbred   (13) f 8wks 2012
Crabbe1 balance beam
with ethanol 		Ethanol i.p. (several doses) vs. control (saline). Missteps count. 3 beam lengths. inbred   (8) both 8wks 2003
Crabbe1 body weight
with ethanol 		Body weight inbred   (8) both 8wks 2003
Crabbe1 grid test
with ethanol 		Ethanol injection (several doses) vs. control (saline). Grid habituation, missteps rate. inbred   (8) both 8wks 2003
Crabbe2 body temperature
with diazepam 		Baseline vs. 30 min after diazepam injection (several doses). inbred   (15) both 6-7wks 1998
Crabbe2 drug and metabolite quantification
with diazepam 		Diazepam (and metabolite) concentration in brain tissue immediately after diazepam injection and rotarod. inbred   (15) both 6-7wks 1998
Crabbe2 monitoring system
with diazepam 		Locomotor activity. Baseline vs. immediately after Diazepam injection (several doses). 15 min test. inbred   (15) both 6-7wks 1998
Crabbe2 rotarod
with diazepam 		Latency to fall from 5 rpm rotarod immediately after diazepam injection. inbred   (15) both 6-7wks 1998
Crabbe3 body weight
with ethanol 		Body weight inbred   (22) both 9-17wks 2003
Crabbe3 rotarod
with ethanol 		Baseline and ethanol i.p. 3 fixed speeds (several doses) and accelerating. inbred   (22) both 9-17wks 2003
Crabbe4 alcohol quantification
with ethanol 		Blood alcohol concentration after ethanol 2 g/kg i.p., several timepoints. inbred   (21) both 9-17wks 2003
Crabbe4 dowel balance test
with ethanol 		Latency to fall 0 min and 30 min post-injection, 2 widths. Ethanol 2 g/kg. inbred   (21) both 9-17wks 2003
Crabbe4 grip strength
with ethanol 		Baseline vs. 30 min after ethanol 2 g/kg i.p. inbred   (21) both 9-17wks 2003
Crabbe4 vertical wire mesh
with ethanol 		Latency to fall 30 min post-injection. Ethanol 2 g/kg i.p. inbred   (21) both 9-17wks 2003
Crabbe5 parallel rod floor test
with ethanol 		Parallel rod balance test, baseline vs. ethanol 2 g/kg i.p.. inbred   (8) both 7-14wks 2005
Crowley1 behavior observation
with haloperidol 		Observed involuntary repetitive movement. Baseline vs. during and after haloperidol 60d implant (several timepoints). inbred w/CC8   (27) m 9-28wks 2012
Crowley1 body weight
with haloperidol 		Baseline vs. after haloperidol 60d implant. inbred w/CC8   (27) m 9-28wks 2012
Crowley1 drug and metabolite quantification
with haloperidol 		Haloperidol concentration (plasma). Baseline vs. during and after haloperidol 60d implant (several timepoints). inbred w/CC8   (27) m 9-28wks 2012
Crowley1 inclined screen test
with haloperidol 		Baseline vs. during and after haloperidol 60d implant (several timepoints). inbred w/CC8   (27) m 9-28wks 2012
Crowley1 open field test
with haloperidol 		Locomotor activity, exploratory behavior, involuntary movement. Baseline vs. haloperidol 60d implant (several timepoints). 60 min test. inbred w/CC8   (27) m 9-28wks 2012
Crusio1 behavior observation Inter-male agression. BXD w/par   (55) both 10-16wks 2018
Crusio1 body weight Body weight BXD w/par   (55) both 10-16wks 2018
Crusio1 histopathology Hippocampal histology. BXD w/par   (55) both 10-16wks 2018
Crusio1 open field test Locomotor activity and exploratory behavior. 20 min test. BXD w/par   (55) both 10-16wks 2018
Crusio1 organ weights Brain weight. BXD w/par   (55) both 10-16wks 2018
Crusio1 radial maze Spatial learning. BXD w/par   (55) both 10-16wks 2018
CSNA02 bottle choice test Palatable food consumption, preference for Boost solution. CC w/par   (18) both 10-39wks 2023
CSNA02 open field test Locomotor response to novelty, habituation. CC w/par   (18) both 10-39wks 2023
CSNA02 operant conditioning chamber Reversal learning (impulsive action) and delay discounting (impulsive choice). CC w/par   (18) both 10-39wks 2023
CSNA03 conditioned place preference test In novel zone: exploration counts, entrance counts, time spent, activity counts, movement counts. CC w/CC8   (61) both 4-25wks 2021
CSNA03 hole board test Number of entries, novel entries, and repeat entries. CC w/CC8   (61) both 4-25wks 2021
CSNA03 in vitro assay Circadian parameters in fibroblast cultures: period, amplitude, phase, damping rate, goodness of fit. CC w/CC8   (61) both 4-25wks 2021
CSNA03 light-dark box Distance traveled, ambulatory time and counts, resting time, stereotypic time and counts, jumping time and counts, vertical time and counts, time in light/dark. CC w/CC8   (61) both 4-25wks 2021
CSNA03 open field test
with cocaine 		Distance traveled, habituation ratio, number of rears, ambulatory time, time in perimeter, corners, and center; cocaine sensitization. CC w/CC8   (61) both 4-25wks 2021
CSNA03 operant conditioning chamber
with cocaine 		Number of infusions, active lever presses, inactive lever presses, intravenous self administration, reversal learning. CC w/CC8   (61) both 4-25wks 2021
Deschepper1 body weight Body weight inbred   (13) both 10wks 2004
Deschepper1 organ weights Heart, kidney, thymus, adrena weights. inbred   (13) both 10wks 2004
Deschepper1 tail cuff Blood pressure. inbred   (13) both 10wks 2004
Dickson1 operant conditioning chamber Sign tracking and goal tracking paradigm with Pavlovian conditioned approach. inbred   (5) both 12-20wks 2015
DiCurzio1 body weight Body weight BXD w/par   (66) both 10wks 2010
DiCurzio1 histopathology Adrenal glands. BXD w/par   (66) both 10wks 2010
DiCurzio1 organ weights Adrenal weight. BXD w/par   (66) both 10wks 2010
Dietrich1 in vitro assay
with Bacillus anthracis lethal toxin 		Bacillus anthracis lethal toxin (anthrax) susceptibility. inbred   (50) f 6-8wks* 1998
DiPetrillo1 urinalysis Microalbumin, creatinine, ratio. inbred w/CC7   (34) m 10wks 2012
DiPetrillo2 urinalysis Microalbumin, creatinine, ratio. CC pre w/par   (163) m 10wks 2012
Donahue1 DXA Body mass, fat mass, lean mass, bone mineral density and content, craniofacial dimensions. inbred w/CC7   (30) both 15-16wks 2002
Donahue1 hormone quantification Osteocalcin, insulin-like growth factor 1. inbred w/CC7   (30) both 15-16wks 2002
Donahue1 metabolic panel Thyroxine (serum). inbred w/CC7   (30) both 15-16wks 2002
Donahue16 DXA Body mass, fat mass, bone mineral density. B6.A consomic w/par   (23) both 24-29wks 2012
Donahue18 body weight Pup body weight at day 3. inbred   (15) f 6-8wks 2010
Donahue18 colony observation Reproduction, fecundity. Litter size, percent survival to day 3. inbred   (15) f 6-8wks 2010
Donahue18 monitoring system Gestation duration and weight gain during pregnancy. inbred   (15) f 6-8wks 2010
Donahue19 body weight Pup body weight at day 3. B6.A consomic w/par   (22) f 6-8wks 2010
Donahue19 colony observation Reproduction, fecundity. Litter size, percent survival to day 3. B6.A consomic w/par   (22) f 6-8wks 2010
Donahue19 monitoring system Gestation duration and weight gain during pregnancy. B6.A consomic w/par   (22) f 6-8wks 2010
Donahue2 biomechanical test Bone strength. inbred   (10) both 16wks 2004
Donahue2 body weight Body weight inbred   (10) both 16wks 2004
Donahue2 bone dimensions Femur. inbred   (10) both 16wks 2004
Donahue2 computed tomography Bone morphology (femur). inbred   (10) both 16wks 2004
Donahue2 DXA Femur bone mineral density and content, thigh cross sectional areas. inbred   (10) both 16wks 2004
Donahue2 muscle weights Quadriceps muscle. inbred   (10) both 16wks 2004
Donahue3 hole board test Exploratory behavior. 10 min test. B6.A consomic w/par   (22) both 6-7wks 2011
Donahue3 open field test Locomotor activity, anxiety-related behavior, involuntary movement. 10 min test. B6.A consomic w/par   (22) both 6-7wks 2011
Donahue4 open field test Locomotor activity, anxiety-related behavior, involuntary repetitive movement. 10 min test. B6.PWD consomic w/par   (28) both 6wks 2011
Donahue5 immune cell quantification White blood cell and immune cell differentials. B6.A consomic w/par   (22) both 7wks 2011
Donahue6 immune cell quantification White blood cell and immune cell differentials. B6.PWD consomic w/par   (28) both 7wks 2011
Donahue7 immunoglobulin quantification Immunoglobulin concentrations (plasma). B6.A consomic w/par   (22) both 9wks 2012
Donahue8 immunoglobulin quantification Immunoglobulin concentrations (plasma). B6.PWD consomic w/par   (28) both 9wks 2011
Donahue9 metabolic panel Clinical blood chemistry (serum). 4h fast. B6.PWD consomic w/par   (25) both 11wks 2011
Esposito1 histopathology Frequency rates of disorders seen during histopathology survey of various organs. inbred   (6) both 2013
Eumorphia1 complete blood count Hematology. inbred   (8) both 12wks 2007
Eumorphia1 lipid profile Cholesterol, HDL, non-HDL, triglycerides, free fatty acids. Plasma. inbred   (8) both 12wks 2007
Eumorphia1 metabolic panel Clinical blood chemistry (plasma). Unknown fast. inbred   (8) both 12wks 2007
Eumorphia2 DXA Body mass, fat mass, lean mass, bone mineral density and content. inbred   (5) both 12, 24, 52 wks 2008
Eumorphia3 glucose tolerance 0 to 180 min after 20% glucose i.p. 16h fast. inbred   (4) both 12, 24, 52 wks 2008
Eumorphia4 intake monitoring Food intake. Daily. inbred   (4) both 12, 24 wks 2008
Eumorphia5 body temperature Hourly readings in cold room. 6h test. inbred   (4) both 12wks 2008
Eumorphia6 echocardiography Cardiovascular function and morphology. inbred   (4) both 12wks 2008
Eumorphia6 organ weights Cardiac ventricle weight. inbred   (4) both 12wks 2008
Eumorphia6 tail cuff Heart rate. inbred   (4) both 12wks 2008
Eumorphia7 immunoglobulin quantification Immunoglobulin concentrations (serum). inbred   (6) both 9-12wks 2008
Everett1 body weight Body weight inbred   (14) both 9-12wks 2003
Everett1 bone dimensions Craniofacial bone dimensions. inbred   (14) both 9-12wks 2003
Evsikova1 body weight Body weight inbred   (14) both 25wks 2009
Evsikova1 intake monitoring Food intake, water intake at 6mo. Light phase, dark phase, total. inbred   (14) both 25wks 2009
Evsikova1 monitoring system Locomotor activity. Aging study. 24h test with 12h light and 12h dark phases. inbred   (14) both 25wks 2009
Ferris1 body weight
with influenza A (H1N1) virus 		Body weight CC pre w/par   (163) f 8-16wks 2012
Ferris1 health assessment
with influenza A (H1N1) virus 		Clinical health assessment score and strain susceptibility index 4 days after infection with influenza A (H1N1) virus. CC pre w/par   (163) f 8-16wks 2012
Ferris1 histopathology
with influenza A (H1N1) virus 		Lungs and airway 4 days after infection with influenza A (H1N1) virus. CC pre w/par   (163) f 8-16wks 2012
Ferris1 in vitro assay
with influenza A (H1N1) virus 		Viral replication log titer 4 days after infection with influenza A (H1N1) virus. In vitro. CC pre w/par   (163) f 8-16wks 2012
Finn1 bottle choice test
with ethanol 		Voluntary consumption of ethanol, and ethanol with saccharin (several doses in water). inbred   (22) both 8-12wks 2007
Flaherty1 elevated zero maze Anxiety-related behaviors. inbred   (8) both 8-9wks 2001
Frankel1 electroconvulsion test
with lamotrigine 		Electroconvulsive thresholds. Lamotrigine. 2 test sites. inbred   (16) both 6-11wks 2000
Gavras1 tail cuff
with sodium chloride 		Heart rate and blood pressure. Sodium chloride (1% solution for 2wks) vs. control. inbred   (11) both 9-12wks 2003
Gershenfeld1 light-dark box
with imipramine 		Anxiety-related behavior. Baseline (saline) vs. imipramine i.p. 10 min test. inbred   (12) m 5-10wks 2003
Gershenfeld1 open field test
with imipramine 		Locomotor activity, exploratory and anxiety-related behavior. Baseline (saline) vs. imipramine i.p. inbred   (12) m 5-10wks 2003
Gershenfeld1 tail suspension test
with imipramine 		Immobility. Baseline (saline) vs. imipramine i.p. 6 min test. inbred   (12) m 5-10wks 2003
GMC01 open field test Locomotor, exploratory, and anxiety-related behavior. 20 min test some at 5 min intervals. inbred w/CC8   (8) both 8-9wks 2020
GMC02 grip strength Several trials. inbred w/CC8   (8) both 8-10wks 2020
GMC03 observation (SHIRPA) Behavior, and neurosensory responses (SHIRPA protocol). inbred w/CC8   (8) both 8-10wks 2020
GMC04 rotarod Latency to fall from accelerating rotarod. inbred w/CC7   (7) both 9-10wks 2020
GMC05 acoustic startle test Acoustic startle response, prepulse inhibition. inbred w/CC8   (8) both 9-10wks 2020
GMC06 lipid profile Cholesterol, HDL, non-HDL, triglycerides, fatty acids. 16h fast, plasma. inbred   (5) both 10-11wks 2020
GMC06 metabolic panel Glucose, glycerol. 16h fast. inbred   (5) both 10-11wks 2020
GMC07 nociception assay Hot plate (two trials). inbred w/CC8   (8) both 11-12wks 2020
GMC08 transepidermal water loss test Transepidermal water loss in condenser chamber. inbred w/CC8   (8) both 11-12wks 2020
GMC09 intake monitoring Food, water intake. 21h test. inbred w/CC8   (8) both 12-13wks 2020
GMC09 monitoring system Locomotor activity and energy metabolism. 21h test. inbred w/CC8   (8) both 12-13wks 2020
GMC10 NMR Body mass, fat and lean tissue mass. inbred w/CC8   (8) both 12-13, 18-19wks 2020
GMC11 glucose tolerance 0 to 120 min after 20% glucose i.p., 16h fast. inbred w/CC8   (6) both 13-14wks 2020
GMC12 echocardiography Cardiovascular function and morphology. inbred w/CC8   (8) both 14-15wks 2020
GMC13 ECG Heart rate and wave intervals. Conscious. inbred   (6) both 14-15wks 2020
GMC14 computed tomography Retinal thickness and fundus vessels. inbred w/CC8   (8) both 14-17wks 2020
GMC14 organ dimensions Axial length of eye. inbred w/CC8   (8) both 14-17wks 2020
GMC14 Scheimpflug imaging Eye lens density. inbred w/CC8   (8) both 14-17wks 2020
GMC14 virtual optomotor Threshold of spatial frequency. inbred w/CC8   (8) both 14-17wks 2020
GMC15 complete blood count Hematology. inbred w/CC8   (8) both 20-21wks 2020
GMC16 lipid profile Cholesterol, triglycerides. No fast, plasma. inbred w/CC8   (8) both 16-17, 20-21wks 2020
GMC16 metabolic panel Clinical blood chemistry (plasma). No fast. inbred w/CC8   (8) both 16-17, 20-21wks 2020
GMC17 ABR test Auditory brainstem response. inbred w/CC7   (7) both 17-18wks 2020
GMC18 body size and weight Body weight and length. inbred w/CC8   (8) both 17-18wks 2020
GMC18 DXA Body mass, fat mass, lean mass, bone mineral density and content, bone area. inbred w/CC8   (8) both 17-18wks 2020
GMC18 X-ray Lumbar vertebrae count. inbred w/CC8   (8) both 17-18wks 2020
GMC19 ventilator Lung, respiratory function. inbred w/CC8   (8) f 21-22wks 2020
GMC20 autoantibody quantification Anti-DNA autoantibodies, rheumatoid factor. inbred w/CC8   (8) both 16-17, 20-21wks 2020
GMC20 immunoglobulin quantification Immunoglobulins (plasma). inbred w/CC8   (8) both 16-17, 20-21wks 2020
GMC21 bone dimensions Tibia bone length. inbred w/CC8   (8) both 20-21wks 2020
GMC21 organ weights Heart, liver, spleen weights. inbred w/CC8   (8) both 20-21wks 2020
GMC22 body weight Body weight and growth curve from 8wks to 21wks. inbred w/CC8   (8) both 8-21wks 2020
Golani1 open field test Locomotor activity, exploratory and anxiety-related behavior. inbred   (8) m 10wks 2003
Gould1 drug and metabolite quantification
with lithium 		Lithium concentration in brain tissue and blood serum after lithium (several doses). inbred   (11) m 7-8wks 2011
Gould1 forced swim test
with lithium 		Lithium (several doses) vs. control. 6 min test. inbred   (11) m 7-8wks 2011
Gould2 behavior observation
with nicotine 		Observed measures of anxiety. Nicotine (high dose) vs. control. 20 min period. inbred   (8) m 8-12wks 2011
Gould2 drug and metabolite quantification
with nicotine 		Amount of nicotine and cotinine in blood plasma after nicotine doses. High and lower doses. inbred   (8) m 8-12wks 2011
Gould2 elevated plus maze
with nicotine 		Measures of anxiety. Nicotine (high dose) vs. control. 5 min test. inbred   (8) m 8-12wks 2011
Gould2 fear conditioning test
with nicotine 		Contextual fear, cued fear. Nicotine (high and several lower doses) vs. control. inbred   (8) m 8-12wks 2011
Gould3 behavior observation
with nicotine 		Observed measures of anxiety during nicotine withdrawal. Nicotine (several high doses) vs. control. inbred   (8) m 8-12wks 2011
Gould3 elevated plus maze
with nicotine 		Measures of anxiety during nicotine withdrawal. Nicotine (several high doses) vs. control. inbred   (8) m 8-12wks 2011
Gould3 fear conditioning test
with nicotine 		Contextual fear, cued fear during nicotine withdrawal. Nicotine (high and several lower doses) vs. control. inbred   (8) m 8-12wks 2011
Gould4 conditioned place preference test
with nicotine 		Nicotine preference and learning effect. Nicotine-treated vs. control. 2 trials (day 5, day 10). inbred   (8) m 8-10wks 2014
Graubert1 complete blood count
with ENU 		Hematology. inbred   (20) both 9wks; 12-64wks 2006
Graubert1 histopathology
with ENU 		Tumor growth frequency rates. ENU mutagen 100 mg/kg vs. control. inbred   (20) both 9wks; 12-64wks 2006
Gros1 genotype assessment
with Candida albicans 		C5 allele sufficiency or deficiency. inbred   (36) f 8-12wks 2011
Gros1 in vitro assay
with Candida albicans 		Susceptibility to infection with Candida albicans. inbred   (36) f 8-12wks 2011
Gros2 health assessment
with Plasmodium chabaudi 		Survival score and susceptibility, Plasmodium chabaudi. inbred   (25) both 8-10wks 2012
Gros2 microscopy
with Plasmodium chabaudi 		Percent of Plasmodium chabaudi-infected erythrocytes in blood. inbred   (25) both 8-10wks 2012
Hadsell1 body weight Daily body weight gain of cross-fostered pups. inbred   (31) f 14-18wks 2012
Hadsell1 colony observation Maternal nurturing study. inbred   (31) f 14-18wks 2012
Hadsell2 mineral quantification concentrations of various minerals in milk inbred   (31) f 14-20wks 2018
Hampton1 ECG Heart rate and wave intervals. Conscious. inbred   (17) both 9-12wks 2001
Handel1 body weight Body weight inbred   (14) m 8-10wks 2010
Handel1 organ weights Male reproductive organ weights. Seminal vesicles, testicles. inbred   (14) m 8-10wks 2010
Handel1 sperm count Sperm count. Hemocytometer. inbred   (14) m 8-10wks 2010
Harrill1 body weight
with isoniazid 		Body weight. Isoniazid-treated vs. control. inbred   (34) f 8-10wks 2011
Harrill1 histopathology
with isoniazid 		Liver pathology scores. Isoniazid-treated vs. control. inbred   (34) f 8-10wks 2011
Harrill1 lipid profile
with isoniazid 		Cholesterol, triglycerides. Hepatic lipids. Isoniazid-treated vs. control. inbred   (34) f 8-10wks 2011
Harrill1 metabolic panel
with isoniazid 		Alanine transaminase. Isoniazid-treated vs. control. inbred   (34) f 8-10wks 2011
Harrill1 organ weights
with isoniazid 		Body, liver, kidney weights. Isoniazid-treated vs. control. inbred   (34) f 8-10wks 2011
Harrill2 biomarker quantification
with DB289 		Kidney injury molecule 1 (KIM-1). DB289-treated vs. control. inbred   (34) f 6-8wks 2012
Harrill2 body weight
with DB289 		DB289-treated vs. control. inbred   (34) f 6-8wks 2012
Harrill2 drug and metabolite quantification
with DB289 		Kidney metabolite (DB75) concentration. DB289-treated vs. control. inbred   (34) f 6-8wks 2012
Harrill2 metabolic panel
with DB289 		Blood urea nitrogen, alanine transaminase, creatinine. DB289-treated vs. control. inbred   (34) f 6-8wks 2012
Harrill2 organ weights
with DB289 		Kidney and liver weights. DB289-treated vs. control. inbred   (34) f 6-8wks 2012
Harrill2 urinalysis
with DB289 		Urine volume, creatinine. DB289-treated vs. control. inbred   (34) f 6-8wks 2012
Haston1 bronchoalveolar lavage assessment
with radiation 		Bronchoalveolar cell differential after exposure to radiation (18 Gy). inbred   (26) both 15-36wks 2012
Haston1 health assessment
with radiation 		Survival rate and health assessment after exposure to radiation. Number of days without respiratory distress (max 26 wks). inbred   (26) both 15-36wks 2012
Haston1 histopathology
with radiation 		Post exposure to radiation. inbred   (26) both 15-36wks 2012
Hawes1 ophthalmoscopy Retinal fundoscopic examination. inbred w/CC7   (41) both 6-7wks 2008
Hawes1 slit lamp Eye morphology. Frequency rates of disorders. inbred w/CC7   (41) both 6-7wks 2008
Hillebrands1 histopathology Kidney pathology at 20mo. inbred   (23) both 87wks 2014
HMDPpheno1 DXA Bone mineral density (whole body, femur, spine). HMDP   (96) m 16wks 2011
HMDPpheno10 metabolite quantification Liver metabolic profiling. Molecular measures of nucleotides, peptides. 16h fast. HMDP   (106) m 16wks 2014
HMDPpheno2 lipid profile Cholesterol, HDL, non-HDL, triglycerides, free fatty acids. 16h fast, plasma. HMDP   (99) m 16wks 2010
HMDPpheno2 NMR Percent fat. HMDP   (99) m 16wks 2010
HMDPpheno3 tail cuff Heart rate and blood pressure. Conscious mice. HMDP   (58) m 9-10wks 2012
HMDPpheno4 fear conditioning test Contextual fear, cued fear. HMDP   (94) m 10wks 2011
HMDPpheno5 complete blood count Hematology. HMDP   (83) m 16wks 2013
HMDPpheno6 metabolite quantification Liver metabolic profiling. Molecular measures of amino acids. 16h fast. HMDP   (106) m 16wks 2014
HMDPpheno7 metabolite quantification Liver metabolic profiling. Molecular measures of carbs, cofactors, vitamins, energy, xenobiotics. 16h fast. HMDP   (106) m 16wks 2014
HMDPpheno8 metabolite quantification Liver metabolic profiling. Molecular measures of lipids (non-lysolipids). 16h fast. HMDP   (106) m 16wks 2014
HMDPpheno9 metabolite quantification Liver metabolic profiling. Molecular measures of lipids (lysolipids). 16h fast. HMDP   (106) m 16wks 2014
Iraqi1 computed tomography
with P.gingivalis and F.nucleatum 		Susceptibility to periodontitis. Mice infected with P. gingivalis and F. nucleatum vs. control. CC pre   (23) both 8wks 2013
Jax1 body weight Body weight and growth curve from age 3wks to 10 wks, weighed weekly. inbred   (24) both 8wks 2000
Jax2 MHC haplotype tissue typing Major histocompatibility complex (MHC) H2 haplotype. inbred   (56) both 2000
Jax3 colony observation Reproductive performance. inbred   (33) f various 1991
Jax4 colony observation Appearance, coat color inbred   (61) both 2006
Jax5 colony observation Reproductive performance. inbred   (35) f various 2009
Jax6 study archive Exome genotype data. Fastq files. inbred   (6) m 2013
Jaxpheno1 body weight Body weight inbred   (11) both 8, 16 wks 2006
Jaxpheno1 DXA Body mass, fat mass, lean mass, bone mineral density and content, bone area. inbred   (11) both 8, 16 wks 2006
Jaxpheno11 study archive
with high-fat diet 		High-fat diet and early stages of type 2 diabetes. one strain: C57BL/6J m 2017
Jaxpheno2 body weight Body weight inbred   (11) both 8, 16 wks 2006
Jaxpheno2 organ weights Brain, heart, kidney, liver, spleen weights. inbred   (11) both 8, 16 wks 2006
Jaxpheno3 lipid profile Cholesterol, HDL, triglycerides, free fatty acids. 4h fast, plasma. inbred   (11) both 8, 16 wks 2006
Jaxpheno3 metabolic panel Clinical blood chemistry (plasma). 4h fast. inbred   (11) both 8, 16 wks 2006
Jaxpheno4 complete blood count Hematology. inbred   (11) both 8, 16 wks 2006
Jaxpheno5 body weight Body weight and growth curve from age 3wks to 16wks, weighed weekly. inbred   (10) both 3-16wks 2014
Jaxpheno6 body weight Body weight inbred   (11) both 8, 16 wks 2006
Jaxpheno6 immune cell quantification White blood cell and immune cell differentials. inbred   (11) both 8, 16 wks 2006
Jaxpheno7 grip strength Peak tension. inbred   (6) m 10wks 2010
Jaxpheno7 observation (SHIRPA) Behavior, and neurosensory responses (SHIRPA protocol). inbred   (6) m 10wks 2010
Jaxpheno7 rotarod Latency to fall from accelerating rotarod. inbred   (6) m 10wks 2010
Jaxpheno8 ABR test Auditory brainstem response. inbred   (7) m 10-13wks 2010
Jaxpheno8 echocardiography Cardiovascular function and morphology. inbred   (7) m 10-13wks 2010
Jaxwest1 body weight Body weight inbred   (7) both 8-14wks 2003
Jaxwest1 DXA Body mass, fat mass, lean mass, bone mineral density and content (whole body, femur, spine). inbred   (7) both 8-14wks 2003
Jaxwest1 ECG Heart rate and wave intervals. Conscious. inbred   (7) both 8-14wks 2003
Jaxwest1 grip strength Peak tension. inbred   (7) both 8-14wks 2003
Jaxwest1 nociception assay Hot plate. inbred   (7) both 8-14wks 2003
Jaxwest1 tail cuff Heart rate and blood pressure. Conscious mice. inbred   (7) both 8-14wks 2003
Jaxwest10 study archive
with glatiramer acetate 		Effect of glatiramer acetate on inflammatory bowel disease induced by dextran sulfate sodium. one strain: C57BL/6J m 2009
Jaxwest4 study archive
with dextran sulfate 		Effects of test compounds on inflammatory bowel disease induced by dextran sulfate sodium one strain: C57BL/6J m 2009
Jaxwest8 study archive
with L-DOPA 		Effect of L-DOPA in inhibiting Parkinsonian pathology. one strain: C57BL/6J m 2009
Jaxwest9 study archive
with captopril 		Effect of captopril on hyperglycemia in a strain with induced type 1 diabetes. one strain: C57BL/6J m 2009
Jentsch1 operant conditioning chamber Reversal learning test. Impulsivity, acquisition, reversal, conditioning. Performance and latency. BXD w/par   (53) m 17wks 2011
Johnson1 ABR test Auditory brainstem response. inbred   (51) both 3-12wks and 15-72wks 2000
Johnson3 ABR test Auditory brainstem response. B6.A consomic w/par   (24) both 23-30wks 2012
Johnson4 ABR test Auditory brainstem response. B6.PWD consomic w/par   (28) both 49-63wks 2012
Jones1 vestibular stimulus test Vestibular function using evoked potentials. inbred   (16) both 49-63wks 2003
Justice2 complete blood count Hematology. inbred   (16) both 12-16wks 2002
Kas1 balance beam Latency to reach target. inbred   (6) m 20-34wks 2009
Kas1 grid test Inverted grid performance. inbred   (6) m 20-34wks 2009
Kas1 home cage monitoring Locomotor activity. inbred   (6) m 20-34wks 2009
Kas1 microscopy Ventral root axon morphology. Nervous system microscopy. inbred   (6) m 20-34wks 2009
Klaassen1 histopathology
with cadmium 		Cadmium-induced toxicity to liver, testis, trigeminal ganglia. inbred   (8) m 8wks 2001
Kliethermes1 hole board test Head dipping and other activity measures, hole board with and without objects in two of the holes. 10 min test. inbred   (14) both 8wks 2006
Kliethermes1 monitoring system Activity in a novel environment. Distance traveled, number of rears. 30 min test. inbred   (14) both 8wks 2006
Kliethermes1 two chamber assay Novel environment preference. Activity in familiar and novel compartments. 20 min test. inbred   (14) both 8wks 2006
Kliethermes1 Y-maze Spontaneous alternation. inbred   (14) both 8wks 2006
Koide1 avoidance test Active and passive. wild-derived Mishima   (11) f 8-13wks 2000
Koide1 home cage monitoring Locomotor activity. wild-derived Mishima   (11) f 8-13wks 2000
Koide1 light-dark box Anxiety-related behavior. wild-derived Mishima   (11) f 8-13wks 2000
Koide1 nociception assay Hot plate and pressure on tail. wild-derived Mishima   (11) f 8-13wks 2000
Koide2 nociception assay Capsaicin intake at several concentrations. wild-derived Mishima   (14) both 8-12wks 2003
Koide3 open field test Exploratory, anxiety-related behavior. 10 min test. wild-derived Mishima   (12) both 10wks 2006
Korstanje1 urinalysis Microalbumin, creatinine, ratio. Aging study, 6mo, 12mo, and 20mo. inbred   (30) both 52, 78, 104 wks 2008
Korstanje2 histopathology Kidney pathology. Aging study, 6mo, 12mo, 20mo. inbred   (29) m 52, 78, 104 wks 2013
Kumar2 open field test Distance traveled, after first 10 min and after 55 min. other   (58) both 7-26wks 2019
Kumar3 body weight Body weight inbred w/CC8   (62) both 8-14wks 2021
Kumar3 open field test Locomotor activity and grooming behavior. inbred w/CC8   (62) both 8-14wks 2021
Kumar4 body size and weight Body length measurements. inbred w/CC8   (62) both 10-20 wks 2021
Kumar4 gait analysis Angular velocity, Stride speed, Step length, Step width, and other gait metrics. inbred w/CC8   (62) both 10-20 wks 2021
Kumar4 open field test Distance traveled. inbred w/CC8   (62) both 10-20 wks 2021
Lake1 complete blood count Hematology. B6.A consomic w/par   (23) both 7-11wks 2005
Lake1 ECG Heart rate and wave intervals. Conscious. B6.A consomic w/par   (23) both 7-11wks 2005
Lake1 lipid profile Cholesterol, HDL, triglycerides, fatty acids. 4h fast, plasma. B6.A consomic w/par   (23) both 7-11wks 2005
Lake1 metabolic panel Glucose, bilirubin, aspartate transaminase (plasma). 4h fast. B6.A consomic w/par   (23) both 7-11wks 2005
Lake1 tail cuff Heart rate and blood pressure. Conscious mice. B6.A consomic w/par   (23) both 7-11wks 2005
Lake2 observation (SHIRPA) Behavior, and neurosensory responses (SHIRPA protocol). B6.A consomic w/par   (23) both 8wks 2005
Lake3 grip strength 3 trials. B6.A consomic w/par   (23) both 8-9wks 2005
Lake3 hole board test Exploratory, locomotor, and anxiety-related behavior. B6.A consomic w/par   (23) both 8-9wks 2005
Lake3 rotarod Latency to fall from fixed and accelerating rotorods, multiple trials. B6.A consomic w/par   (23) both 8-9wks 2005
Lesage1 immune cell quantification Immunological cell variation. CC w/par   (76) both 5-8wks 2018
Lesage2 immune cell quantification total number of splenocytes, number of B cells in spleen, and percentage of splenocytes that are B cells CC w/par   (76) both 5-8wks 2024
Lightfoot1 body weight Body weight inbred   (41) both 8-9wks 2010
Lightfoot1 running wheel monitoring Distance, duration, speed. inbred   (41) both 8-9wks 2010
Lionikas1 body weight
with exercise 		Exercise (swim endurance training regimen) vs. control at weekly intervals for 5wks. inbred   (6) m 11-14wks 2012
Lionikas1 bone dimensions
with exercise 		Femur length. Exercised (swim endurance training regimen) vs. control at weekly intervals for 5wks. inbred   (6) m 11-14wks 2012
Lionikas1 microscopy
with exercise 		Muscle fibers. Exercised (swim endurance training regimen) vs. control at weekly intervals for 5wks. inbred   (6) m 11-14wks 2012
Lionikas1 muscle weights
with exercise 		Various muscles. Exercised (swim endurance training regimen) vs. control at weekly intervals for 5wks. inbred   (6) m 11-14wks 2012
Lionikas1 organ weights
with exercise 		Heart weight. Cardiac ventricle weight. Exercised (swim endurance training regimen) vs. control at weekly intervals for 5wks. inbred   (6) m 11-14wks 2012
Lionikas1 protein activity assessment
with exercise 		Muscle enzyme levels. Exercised (swim endurance training regimen) vs. control at weekly intervals for 5wks. inbred   (6) m 11-14wks 2012
Lionikas1 swim endurance test
with exercise 		Exercise vs. control, weekly for 5wks. inbred   (6) m 11-14wks 2012
Loos1 home cage monitoring Locomotor activity, avoidance, sheltering, habituation, preference index, aversion index, over several days. inbred   (8) m 8-19wks 2012
Loos2 home cage monitoring Locomotor activity, sheltering, habituation. 3 day home-cage assessment. inbred w/CC7   (11) m 8-12wks 2016
Marchuk1 histopathology Cerebral infarct volume, stroke susceptibility. Surgical occlusion of distal medial cerebral artery (MCA) to induce ischemia. inbred   (16) both 11-13wks 2009
Massett1 body weight Body weight inbred   (34) both 8wks 2012
Massett1 treadmill endurance test Duration, distance, work. inbred   (34) both 8wks 2012
Mathes1 body weight
with exercise 		Baseline vs. after exercise (access to running wheel). CC pre w/par   (184) m 10-12wks 2011
Mathes1 intake monitoring
with exercise 		Caloric intake. Baseline vs. after exercise (access to running wheel). Metabolism, food intake. CC pre w/par   (184) m 10-12wks 2011
Mathes1 monitoring system
with exercise 		Respiratory exchange ratio. Baseline (before access to running wheel). CC pre w/par   (184) m 10-12wks 2011
Mathes1 MRI
with exercise 		Body composition (percent fat). Baseline vs. after exercise (access to running wheel). CC pre w/par   (184) m 10-12wks 2011
Mathes1 running wheel monitoring
with exercise 		Distance, speed at days 1, 6, and 12. CC pre w/par   (184) m 10-12wks 2011
Maurer1 body weight
with atenolol, isoproterenol 		Isoproterenol or atenolol vs. control. inbred   (23) m 10-12wks 2009
Maurer1 ECG
with atenolol, isoproterenol 		Heart rate and wave amplitudes and intervals. Unconscious. Isoproterenol or atenolol vs. control. inbred   (23) m 10-12wks 2009
Maurer1 organ weights
with atenolol, isoproterenol 		Heart, atria, ventricle weights. Isoproterenol or atenolol vs. control. inbred   (23) m 10-12wks 2009
Maurer1 tail cuff
with atenolol, isoproterenol 		Heart rate and blood pressure. Conscious mice. Isoproterenol or atenolol vs. control. inbred   (23) m 10-12wks 2009
Metten1 behavior observation
with ethanol 		Observed gait, hindlimb splay 10 min and 30 min after ethanol i.p. (several doses). inbred   (9) both 8-11wks 2004
Metten1 open field test
with ethanol 		Locomotor activity. Ethanol i.p. (several doses) vs. control (saline i.p.). 45s test. inbred   (9) both 8-11wks 2004
Metten2 behavior observation
with ethanol 		Ethanol withdrawal severity and handling-induced convulsions. inbred   (15) m 8-11wks 2005
Metten2 body weight
with ethanol 		Body weight inbred   (15) m 8-11wks 2005
Mills1 apoptosis assessment Aging study, 6mo, 12mo, 20mo. inbred   (30) both 26, 52, 87 wks 2008
Mills1 chromosome instability assessment Chromosome instability. Aging study, 6mo, 12mo, 20mo. inbred   (30) both 26, 52, 87 wks 2008
Mitchell1 bottle choice test Sucrose vs. water. inbred   (15) m 5-7wks 2010
Mitchell1 go/no-go task Pre-cue, go cue. no-go cue. Discrimination index. inbred   (15) m 5-7wks 2010
Mitchell1 monitoring system Locomotor activity. inbred   (15) m 5-7wks 2010
Mogil1 nociception assay Battery of tests for mechanical, chemical, thermal nociception. inbred   (12) m 6-18wks 2002
Mogil2 monitoring system Locomotor activity. Light and dark phases. inbred   (12) m 6-10wks 2000
Mogil3 nociception assay von Frey nociception test, baseline and after spared nerve injury (SNI) surgery as a hypersensitizer. inbred   (18) both 7-12wks 2012
Mooney1 protein activity assessment Acetylcholinesterase activity of cerebellum and dorsal and ventral hippocampus inbred   (20) m 8-12wks 2021
Morgan1 body weight
with high-fat diet and olanzapine 		Body weight and growth curve from age 8wks to 18wks weighed every 2wks. Olanzapine vs. control (both groups high-fat diet). inbred w/CC8   (9) f 8-18wks 2014
Moy1 three chamber assay Sociability and preference for social novelty. Autism-relevant behaviors. inbred   (17) m 6-7wks 2008
Nadeau1 body weight
with high-fat diet 		Baseline vs. high-fat diet for 12wks. B6.A consomic w/par   (24) m 5, 17 wks 2008
Nadeau2 body size and weight
with high-fat high-sucrose diet 		Body weight, size, and body mass index after 16wks on high-fat high-sucrose diet. B6.A consomic w/par   (24) m 5, 21 wks 2015
Nadeau2 lipid profile
with high-fat high-sucrose diet 		Cholesterol, triglycerides. 16h fast, plasma. Hepatic triglycerides. B6.A consomic w/par   (24) m 5, 21 wks 2015
Nadeau2 metabolic panel
with high-fat high-sucrose diet 		Glucose, insulin, insulin resistance after 16wks of high-fat high-sucrose diet. 16h fast. B6.A consomic w/par   (24) m 5, 21 wks 2015
Nadeau2 organ weights
with high-fat high-sucrose diet 		Liver weight after 16wks of high-fat high-sucrose diet. 16h fast. B6.A consomic w/par   (24) m 5, 21 wks 2015
Nadeau3 body size and weight
with high-fat high-sucrose diet 		Body weight and body mass index after 16 wks of high-fat high-sucrose diet. inbred   (2) m 21 wks 2016
Nadeau3 body weight
with high-fat high-sucrose diet 		After 16 wks on high-fat high-sucrose diet. inbred   (2) m 21 wks 2016
Nadeau3 hormone quantification
with high-fat high-sucrose diet 		Insulin and insulin resistance after 16 wks of high-fat high-sucrose diet. Overnight fast. inbred   (2) m 21 wks 2016
Nadeau3 lipid profile
with high-fat high-sucrose diet 		Cholesterol and triglycerides. Overnight fast, plasma. Hepatic triglycerides. inbred   (2) m 21 wks 2016
Nadeau3 organ weights
with high-fat high-sucrose diet 		Liver weight after 16 wks of high-fat high-sucrose diet. Overnight fast. inbred   (2) m 21 wks 2016
Nadeau4 body size and weight
with high-fat high-sucrose diet 		Body length and body mass index after high-fat high-sucrose diet for 14-15 wks B6.A consomic w/par   (3) m 4-19 wks 2016
Nadeau4 body weight
with high-fat high-sucrose diet 		High-fat high-sucrose diet for 14-15 wks B6.A consomic w/par   (3) m 4-19 wks 2016
Naggert1 body weight
with high-fat diet 		High-fat diet for 8wks. inbred w/CC7   (43) both 5, 21 wks 2003
Naggert1 DXA
with high-fat diet 		Body mass, fat mass, lean mass, bone mineral density and content after 8wks on high-fat diet. inbred w/CC7   (43) both 5, 21 wks 2003
Naggert1 hormone quantification
with high-fat diet 		Insulin and leptin after 18wks on high-fat diet. Multiple readings per animal were averaged. inbred w/CC7   (43) both 5, 21 wks 2003
Naggert1 metabolic panel
with high-fat diet 		Glucose (plasma). Baseline vs. high-fat diet (17wks). 4h fast. inbred w/CC7   (43) both 5, 21 wks 2003
Odet1 body weight Body weight inbred   (8) m 10-66wks 2015
Odet1 histopathology Male reproductive histopathology. Percent normal vs. abnormal sperm, seminiferous tubules. inbred   (8) m 10-66wks 2015
Odet1 metabolic panel Male reproductive sperm lactate production. inbred   (8) m 10-66wks 2015
Odet1 organ weights Male reproductive organ weights. Testes, seminal vesicles, epididymis, vas deferens. inbred   (8) m 10-66wks 2015
Odet1 sperm count Sperm count. Hemocytometer. inbred   (8) m 10-66wks 2015
Odet2 microscopy Male reproductive sperm motility. inbred w/CC8   (8) m 10-66wks 2015
Paigen1 body weight
with high-fat diet 		Baseline vs. high-fat diet for 8wks. inbred   (44) both 15-19wks 2000
Paigen1 histopathology
with high-fat diet 		Gallstone, gallbladder, and atherosclerosis lesion histopathology after 8wks on high-fat diet. inbred   (44) both 15-19wks 2000
Paigen1 lipid profile
with high-fat diet 		Cholesterol, HDL, non-HDL. 4h fast, plasma. Hepatic lipids. 8wks on high-fat diet. inbred   (44) both 15-19wks 2000
Paigen1 metabolic panel
with high-fat diet 		Alanine transaminase, bile salts (plasma) after 8wks on high-fat diet. 4h fast. inbred   (44) both 15-19wks 2000
Paigen1 organ dimensions
with high-fat diet 		Gallbladder volume after 8wks on high-fat diet. inbred   (44) both 15-19wks 2000
Paigen1 organ weights
with high-fat diet 		Liver weight after 8wks on high-fat diet. inbred   (44) both 15-19wks 2000
Paigen2 histopathology
with high-fat diet 		Aortic lesion size histopathology. Baseline vs. high-fat diet (17wks). inbred w/CC7   (43) both 7-9wks, 24-27wks 2002
Paigen2 lipid profile
with high-fat diet 		Cholesterol, HDL, non-HDL, triglycerides. Baseline vs. high-fat diet (17wks). 4h fast, plasma. inbred w/CC7   (43) both 7-9wks, 24-27wks 2002
Paigen3 body weight
with high-fat diet 		Baseline vs. high-fat diet for 8wks. obesity mutants   (8) both 15-19wks 2000
Paigen3 histopathology
with high-fat diet 		Gallstone, gallbladder, and atherosclerosis lesion histopathology after 8wks on high-fat diet obesity mutants   (8) both 15-19wks 2000
Paigen3 lipid profile
with high-fat diet 		Cholesterol, HDL, non-HDL. 4h fast, plasma. Hepatic lipids. 8wks on high-fat diet. obesity mutants   (8) both 15-19wks 2000
Paigen3 metabolic panel
with high-fat diet 		Alanine transaminase, bile salts (plasma) after 8wks on high-fat diet. 4h fast. obesity mutants   (8) both 15-19wks 2000
Paigen3 organ dimensions
with high-fat diet 		Gallbladder volume after 8wks on high-fat diet obesity mutants   (8) both 15-19wks 2000
Paigen3 organ weights
with high-fat diet 		Liver weight after 8wks on high-fat diet. obesity mutants   (8) both 15-19wks 2000
Paigen4 lipid profile Cholesterol, HDL, non-HDL, triglycerides. 4h fast, plasma. inbred w/CC7   (43) both 10wks 2002
Palmer1 fear conditioning test Innate anxiety-like behavior and contextual fear conditioning. B6.A consomic w/par   (19) both 10wks 2007
Palmer2 open field test
with methamphetamine 		Locomotor activity and habituation. Baseline (saline) vs. methamphetamine 2 mg/kg i.p. 30 min test. B6.A consomic w/par   (21) both 10wks 2008
Palmer5 acoustic startle test Acoustic startle response, prepulse inhibition. F1 Tcf7l2   (30) both 7-14wks 2017
Palmer5 body weight Body weight F1 Tcf7l2   (30) both 7-14wks 2017
Palmer5 fear conditioning test Contextual fear, cued fear. F1 Tcf7l2   (30) both 7-14wks 2017
Palmer5 forced swim test Immobility time. 6 min test. F1 Tcf7l2   (30) both 7-14wks 2017
Palmer5 metabolic panel Glucose (blood). Before and after 16h fast. F1 Tcf7l2   (30) both 7-14wks 2017
Palmer5 open field test Locomotor and exploratory behavior. 30 min test. F1 Tcf7l2   (30) both 7-14wks 2017
Palmer6 acoustic startle test
with methamphetamine 		Acoustic startle response. F1 Cacna1c   (30) both 7-14wks 2017
Palmer6 body weight
with methamphetamine 		Body weight F1 Cacna1c   (30) both 7-14wks 2017
Palmer6 forced swim test
with methamphetamine 		Immobility time. 6 min test. F1 Cacna1c   (30) both 7-14wks 2017
Palmer6 light-dark box
with methamphetamine 		Anxiety-related. 5 min test. F1 Cacna1c   (30) both 7-14wks 2017
Palmer6 open field test
with methamphetamine 		Locomotor and exploratory activity, anxiety-related behavior, methamphetamine sensitivity. 30 min test. F1 Cacna1c   (30) both 7-14wks 2017
Perlegen2 genotyping SNP profiling, 8,100,000+ genomic locations, 1-19,X,Y,MT. inbred   (16) m 2005
Peters1 coagulation test Fibrinogen. inbred w/CC7   (43) both 10wks 2001
Peters1 complete blood count Hematology. inbred w/CC7   (43) both 10wks 2001
Peters3 complete blood count Hematology. Variation over time of controls. one strain: C57BL/6J both 2005
Peters4 complete blood count Hematology. Aging study, 6mo, 12mo, 18mo, 24mo. inbred   (30) both 26, 52, 78, 104 wks 2007
Petkova1 complete blood count Hematology. Aging study, 6mo, 12mo, 18mo, 24mo. inbred   (32) both 26, 52, 78, 104 wks 2007
Petkova1 immune cell quantification Aging study, 6mo, 12mo, 18mo, 24mo. inbred   (32) both 26, 52, 78, 104 wks 2007
Petryshen1 acoustic startle test Acoustic startle response, prepulse inhibition. B6.A consomic   (22) m 7-9wks 2009
Pletcher1 body weight Body weight inbred   (32) m 7-9wks 2007
Pletcher1 hormone quantification Corticosterone (serum). inbred   (32) m 7-9wks 2007
Pletcher1 open field test Locomotor and anxiety-related behavior. 10 min test. inbred   (32) m 7-9wks 2007
Pletcher1 tail suspension test Immobility percentage. inbred   (32) m 7-9wks 2007
Poon1 histopathology Cell proliferation in the rostral migratory stream. BrdU+ cells. inbred   (9) both 13-78wks 2013
Powell1 in vitro assay
with Neisseria musculi 		Bacterial load after inoculation with Neisseria musculi. Oral cavity. inbred w/CC8   (8) both 8-16wks 2018
Puk1 organ dimensions Eye morphology. inbred   (4) both 13wks 2006
Reed1 body size and weight Body weight, body length, body mass index. inbred   (28) m 8, 12 wks 2009
Reed1 fat pad weights Epididymal, retroperitoneal. inbred   (28) m 8, 12 wks 2009
Reed1 organ weights Heart, kidney weights. inbred   (28) m 8, 12 wks 2009
Rhodes1 body weight
with exercise 		Exercise wheel group vs. control group. inbred   (12) both 8-15wks 2010
Rhodes1 microscopy
with exercise 		Examination of hippocampus dentate gyrus. Exercise wheel group vs. control group. inbred   (12) both 8-15wks 2010
Rhodes1 running wheel monitoring
with exercise 		Locomotor activity. Exercise wheel group vs. control group. Distance per day. inbred   (12) both 8-15wks 2010
Rice1 proteomic profiling Hair proteomics analysis. Spectral counts for 46 specific proteins. inbred   (11) both 10-19wks 2012
Richfield1 neurotransmitter quantification Neurotransmitters. Molecular measures. inbred   (15) m 7-9wks 2003
Richfield1 open field test Locomotor activity. 3 day trials. 45 min sessions. inbred   (15) m 7-9wks 2003
Rosen1 histopathology Midsagittal area of corpus callosum. BXD w/par   (78) both various 2012
Rosen2 histopathology Lateral septal nucleus volume. BXD w/par   (71) both various 2012
Rusyn2 drug and metabolite quantification
with trichloroethylene 		Trichloroethylene metabolites in serum, 2h, 4h, 24h after trichoroethylene exposure. inbred   (17) m 7wks 2010
Rusyn2 metabolic panel
with trichloroethylene 		Blood urea nitrogen, alanine transaminase, aspartate transaminase (serum). Baseline and trichloroethylene-exposed (several timepoints). No fast. inbred   (17) m 7wks 2010
Rusyn6 drug and metabolite quantification
with trichloroethylene 		Trichloroethylene metabolite in blood, liver, kidney after trichloroethylene exposure. inbred   (7) m 6-7wks 2014
Rusyn6 histopathology
with trichloroethylene 		Kidney histopathology evaluation after trichloroethylene exposure, relative to controls. inbred   (7) m 6-7wks 2014
Rusyn6 metabolic panel
with trichloroethylene 		Blood urea nitrogen (serum). Trichloroethylene-exposed vs. control. inbred   (7) m 6-7wks 2014
Rusyn6 organ weights
with trichloroethylene 		Liver, kidney weights. Trichloroethylene-exposed vs. control. inbred   (7) m 6-7wks 2014
Rusyn6 RNA expression profiling
with trichloroethylene 		Trichloroethylene effect on mRNA gene expression in liver and kidney, relative to controls. inbred   (7) m 6-7wks 2014
Rusyn9 study archive
with tetrachloroethylene 		Nonalcoholic fatty liver disease states, toxicokinetics of tetrachloroethylene exposure. one strain: C57BL/6J m 2017
Sandell1 health assessment Post-injury wound healing. Ear cartilage and articular cartilage. LGXSM w/par   (15) both 6-7wks 2012
Sandell1 histopathology Post-injury wound healing. Articular cartilage at 12wks and 16wks post-injury. LGXSM w/par   (15) both 6-7wks 2012
Sanger4 genotyping SNP profiling, 80,000,000+ genomic locations. SNPs and indels. 1-19,X. inbred   (37) both 2017
Schalkwyk1 elevated plus maze Anxiety-related and exploratory behavior. 5 min test. inbred   (8) m 9-11wks 2010
Schalkwyk1 light-dark box Anxiety-related behavior. inbred   (8) m 9-11wks 2010
Schalkwyk1 Morris water maze Spatial learning and memory. Multiple trials. inbred   (8) m 9-11wks 2010
Schalkwyk1 open field test Locomotor activity and exploratory behavior. 5 min test. inbred   (8) m 9-11wks 2010
Schalkwyk1 puzzle box Learning and memory. inbred   (8) m 9-11wks 2010
Schalkwyk1 tail suspension test Duration of immobility. Two trials. inbred   (8) m 9-11wks 2010
Schalkwyk2 RNA expression profiling Hippocampal microRNA expression. Normalized data. BXD w/par   (26) m 15-16wks 2012
Schauwecker1 health assessment
with pilocarpine 		Study of pilocarpine effect on epilepticus seizures. inbred   (11) m 8-10wks 2012
Schonfeld1 body weight Body weight inbred   (11) both 8-10wks 2005
Schonfeld1 DXA Fat mass. inbred   (11) both 8-10wks 2005
Schonfeld1 glucose tolerance 0 to 120 min after 10% glucose i.p. 5h fast. inbred   (11) both 8-10wks 2005
Schonfeld1 hormone quantification Insulin level, 30 min post-injection in glucose tolerance test. 10% glucose. 5h fast. inbred   (11) both 8-10wks 2005
Schonfeld1 insulin tolerance 0 to 120 min after insulin i.p. 5h fast. inbred   (11) both 8-10wks 2005
Schonfeld1 lipid profile Cholesterol, triglycerides, free fatty acids, phospholipids. 5h fast, plasma. Hepatic triglycerides. inbred   (11) both 8-10wks 2005
Schonfeld1 metabolic panel Glucose, beta-hydroxybutyrate (plasma). No fast. inbred   (11) both 8-10wks 2005
Schonfeld1 organ weights Liver weight. inbred   (11) both 8-10wks 2005
Schoonjans1 biomarker quantification
with high-fat diet 		Bile acid levels in plasma, feces, and liver. BXD w/par   (36) m 8-29 wks 2022
Schoonjans1 body weight
with high-fat diet 		At 8, 20 and 29 wks of age. BXD w/par   (36) m 8-29 wks 2022
Schoonjans1 glucose tolerance
with high-fat diet 		Plasma glucose levels at 0, 30, 60 min post oral gavage of Ensure Plus, overday fast. BXD w/par   (36) m 8-29 wks 2022
Schoonjans1 organ dimensions
with high-fat diet 		Small intestine length. BXD w/par   (36) m 8-29 wks 2022
Schoonjans1 organ weights
with high-fat diet 		Liver, spleen, kidney, fat pads, muscles, cecum. BXD w/par   (36) m 8-29 wks 2022
Schughart1 body weight
with influenza A (H1N1) virus 		Influenza A (H1N1) virus vs. baseline. Several timepoints. inbred   (9) both 10-12wks 2009
Schughart1 health assessment
with influenza A (H1N1) virus 		Strain susceptibility score, influenza A (H1N1) virus. inbred   (9) both 10-12wks 2009
Schughart2 body weight
with influenza A (H1N1) virus 		Influenza A (H1N1) virus vs. baseline. Several timepoints.. BXD w/par   (56) f 9-18wks 2012
Schughart2 health assessment
with influenza A (H1N1) virus 		Survival rate, susceptibility, influenza A (H1N1) virus. BXD w/par   (56) f 9-18wks 2012
Schughart3 body weight
with influenza A (H3N2) virus 		Influenza A (H3N2) virus (several doses) vs. baseline. Several timepoints. inbred w/CC8   (8) both 7-13wks 2013
Schughart3 health assessment
with influenza A (H3N2) virus 		Survival rate, susceptibility, influenza A (H3N2) virus (several doses). inbred w/CC8   (8) both 7-13wks 2013
Schughart4 body weight
with influenza A (H3N2) virus 		Influenza A (H3N2) virus vs. controls. Several timepoints. inbred w/CC8   (8) f 8-12wks 2016
Schughart4 complete blood count
with influenza A (H3N2) virus 		White blood cell count and differentials. Influenza A (H3N2) virus vs. controls. inbred w/CC8   (8) f 8-12wks 2016
Schughart4 in vitro assay
with influenza A (H3N2) virus 		Viral load in lungs after infection with influenza A (H3N2) virus. inbred w/CC8   (8) f 8-12wks 2016
Schughart5 body weight
with influenza A (H3N2) virus 		Influenza A (H3N2) virus vs. controls. Several timepoints. inbred w/CC8   (8) f 8-12wks 2016
Schughart5 organ weights
with influenza A (H3N2) virus 		Lung weight. Animals infected with influenza A (H3N2) virus vs. controls. inbred w/CC8   (8) f 8-12wks 2016
Schulz1 body weight Body weight inbred   (7) both 9-18wks 2000
Schulz1 ventilator Lung, respiratory function. inbred   (7) both 9-18wks 2000
Schwartz2 bronchoalveolar lavage assessment
with ovalbumin 		Lung inflammatory changes. Ovalbumin vs. control. inbred   (8) m 6-8wks 2001
Schwartz3 study archive Lung, respiratory response to lipopolysaccharide endotoxin. inbred   (10) both 2003
Schwartz4 study archive Lung, respiratory response to ozone. Methacholine-sensitized. inbred   (8) both 2004
Schwartz5 study archive Lung, respiratory response to Streptococcus zooepidemicus. inbred   (8) both 2007
Seburn1 body weight Body weight inbred   (16) both 7-9wks 2001
Seburn1 intake monitoring Food, caloric, and water intake. Daily. inbred   (16) both 7-9wks 2001
Seburn1 monitoring system Locomotor activity and energy metabolism. 24h test. inbred   (16) both 7-9wks 2001
Seburn2 gait analysis Aging study, 6mo, 18mo. inbred   (32) both 26, 52, 78, 104 wks 2008
Seburn2 grip strength Peak tension. 3 trials. Aging study, 6mo, 12mo, 18mo, 24mo. inbred   (32) both 26, 52, 78, 104 wks 2008
Shin1 elevated plus maze Exploratory and anxiety-related behaviors. 5 min test. inbred   (11) m 12-14wks 2016
Shin1 fear conditioning test Pavlovian fear conditioning. inbred   (11) m 12-14wks 2016
Shin1 observational fear learning test Percent time freezing to conditioning and contextual exposure. inbred   (11) m 12-14wks 2016
Shin1 open field test Locomotor activity and exploratory behavior. 5 min test. inbred   (11) m 12-14wks 2016
Shin1 three chamber assay Sociability testing. Tolerance of a novel mouse, a novel object, and second novel mouse vs. first. 10 min test. inbred   (11) m 12-14wks 2016
Shockley1 body weight
with high-fat diet 		High-fat diet for 4wks vs. control. inbred   (10) both 10-13wks 2008
Shockley1 lipid profile
with high-fat diet 		Cholesterol, HDL, triglycerides, fatty acids. High-fat diet (4wks) vs. control. 5h fast, serum. inbred   (10) both 10-13wks 2008
Shockley1 metabolic panel
with high-fat diet 		Clinical blood chemistry measures (serum). High-fat diet (4wks) vs. control. inbred   (10) both 10-13wks 2008
Shorter3 colony observation Litter size assessment. CC diallel w/par   (62) f 3wks 2018
Spijker1 acoustic startle test Acoustic startle response, prepulse inhibition. BXD w/par   (45) m 8wks 2011
Spijker1 choice serial reaction time task Choice serial reaction time task. Impulsivity, attention, cognitive flexibility behavior. BXD w/par   (45) m 8wks 2011
Spijker2 choice serial reaction time task Choice serial reaction time task. Impulsivity, attention, cognitive flexibility behavior. 25 min test. inbred   (12) m 6wks 2009
Spijker2 elevated plus maze Exploratory and anxiety-related behaviors. 5 min test. inbred   (12) m 6wks 2009
Spijker2 home cage monitoring Exploratory behavior. 4 min and 10 min tests. inbred   (12) m 6wks 2009
Spijker2 light-dark box Anxiety, avoidance behavior. 5 min test. inbred   (12) m 6wks 2009
Spijker2 open field test Locomotor activity and exploratory behavior. 10 min test. inbred   (12) m 6wks 2009
Stahl1 study archive Hematology and clinical chemistry reference levels. one strain: C57BL/6J both 6-10wks 2018
Sugiyama1 tail cuff Heart rate and blood pressure. Conscious mice. inbred   (25) m 10wks 2007
Sundberg1 study archive Histopathology. Aging study. inbred   (28) both 2008
Sunde1 body weight
with selenium 		Body weight curve 3 to 12 wks, control group. inbred w/CC8   (8) m 3-14wks 2018
Sunde1 RNA expression profiling
with selenium 		Selenium regulation of selenoprotein enzyme activity and transcripts. inbred w/CC8   (8) m 3-14wks 2018
Svenson1 tail cuff Heart rate and blood pressure. Conscious mice. inbred   (14) both 9wks 2004
Svenson3 coagulation test Fibrinogen, anti-thrombin III, factor VIII B6.PWD consomic w/par   (28) both 9wks 2006
Svenson3 complete blood count Hematology. B6.PWD consomic w/par   (28) both 9wks 2006
Svenson3 lipid profile Cholesterol, HDL, triglycerides, free fatty acids. 4h fast, plasma. B6.PWD consomic w/par   (28) both 9wks 2006
Svenson3 metabolic panel Glucose, bilirubin, blood urea nitrogen, aspartate transaminase (plasma). 4h fast. B6.PWD consomic w/par   (28) both 9wks 2006
Svenson4 body size and weight Body weight, body length, body mass index. B6.PWD consomic w/par   (28) both 16wks 2006
Svenson4 DXA Body mass, fat mass, lean mass, bone mineral density and content. B6.PWD consomic w/par   (28) both 16wks 2006
Taft1 assisted reproduction Performance following assisted reproductive technologies. inbred   (10) f various 2006
Tarantino1 body weight
with cocaine 		Body weight inbred   (45) m 8-11wks 2015
Tarantino1 open field test
with cocaine 		Locomotor activity. Baseline (saline) vs. cocaine 20 mg/kg i.p. 30 min test. inbred   (45) m 8-11wks 2015
Tarantino2 forced swim test
with ovariectomy 		Mice with ovariectomy surgery vs. controls (sham surgery), 6 min test. inbred   (37) f 8-10wks 2016
Tarantino2 open field test
with ovariectomy 		Locomotor activity and exploratory behavior. Mice with ovariectomy surgery vs. controls (sham surgery), 10 min test. inbred   (37) f 8-10wks 2016
Thomsen1 open field test
with cocaine 		Locomotor activity. Baseline (saline) vs. cocaine i.p. (several doses). 1.3h and 2.3 h duration. inbred   (15) both 8-10wks 2011
Thomsen2 open field test
with R-6-Br-APB, quinelorane 		Locomotor activity. Baseline (saline) vs. dopamine agonists i.p. (several doses). 3h session. inbred   (15) both 8-10wks 2011
Threadgill1 biomarker quantification
with acetaminophen 		Liver cytochrome isoforms. Acetaminophen vs. control. 18h fast. inbred w/CC7   (37) m 8-17wks 2005
Threadgill1 histopathology
with acetaminophen 		Liver histopathology, necrosis after acetaminophen vs. control. 18h fast. inbred w/CC7   (37) m 8-17wks 2005
Threadgill1 metabolic panel
with acetaminophen 		Blood urea nitrogen, alanine transaminase, aspartate transaminase (serum), liver enzyme homeostasis. Acetaminophen (several doses) vs. control, several timepoints post-Rx. 18h fast. inbred w/CC7   (37) m 8-17wks 2005
Threadgill1 metabolite quantification
with acetaminophen 		Liver protein homeostasis. Acetaminophen vs. control. 18h fast. inbred w/CC7   (37) m 8-17wks 2005
Threadgill1 organ weights
with acetaminophen 		Liver weight after acetaminophen (several doses) vs. control. 18h fast. inbred w/CC7   (37) m 8-17wks 2005
Threadgill2 drug and metabolite quantification
with acetaminophen 		Acetaminophen metabolite concentrations (serum) and liver protein homeostasis. Baseline vs. acetaminophen (several doses, several timepoints). inbred   (5) m 6-8wks 2005
Threadgill2 histopathology
with acetaminophen 		Liver histopathology, necrosis, injury after acetaminophen vs. control. 18h fast. inbred   (5) m 6-8wks 2005
Threadgill2 metabolic panel
with acetaminophen 		Alanine transaminase (serum). Acetaminophen (several doses) vs. control. inbred   (5) m 6-8wks 2005
Threadgill2 metabolite quantification
with acetaminophen 		Glutathione. inbred   (5) m 6-8wks 2005
Tomasini1 biomarker quantification Fibronectin. inbred   (25) both 9wks 2007
Tordoff1 body weight Body weight during testing. inbred   (28) m 9wks 2001
Tordoff1 bottle choice test Various salt solutions (several concentrations) vs. water. inbred   (28) m 9wks 2001
Tordoff2 body weight Body weight inbred   (28) m 4-12wks 2001
Tordoff2 intake monitoring Food intake, water intake. Daily. inbred   (28) m 4-12wks 2001
Tordoff3 body weight Body weight inbred w/CC7   (40) both 9-15wks 2002
Tordoff3 bottle choice test Various salt solutions (several concentrations) vs. water. inbred w/CC7   (40) both 9-15wks 2002
Tordoff3 DXA Body mass, fat mass, lean mass, bone mineral density and content. inbred w/CC7   (40) both 9-15wks 2002
Tordoff3 metabolic panel Ionized and total blood calcium, blood pH. inbred w/CC7   (40) both 9-15wks 2002
Tordoff3 monitoring system Bleeding time to collect approx 30 µL. inbred w/CC7   (40) both 9-15wks 2002
Trullas1 elevated plus maze Exploratory and anxiety-related behaviors. 5 min test. inbred   (16) m 6-8wks 1993
Trullas1 hormone quantification Corticosterone levels (plasma). Baseline vs. after stress (30 min in restraining cage). inbred   (16) m 6-8wks 1993
Trullas1 monitoring system Novelty-induced fear test. Eating inhibition due to novelty of environment. 10 min test. inbred   (16) m 6-8wks 1993
Trullas1 open field test Locomotor activity under dim lights vs. bright lights. 5 min test. inbred   (16) m 6-8wks 1993
UCLA1 genotyping SNP profiling, 132,000+ genomic locations, 1-19,X HMDP   (248) both 2018
UNC-GMUGA1 genotyping SNP profiling, 130,000+ genomic locations, 1-19,X,Y,MT. CC w/par   (77) m 2020
UNC-MMUGA2 genotyping SNP profiling, 76,000+ genomic locations, 1-19,X,MT CC w/par   (77) both 2017
Vinyard1 body weight Body weight inbred   (21) both 6-8wks 2009
Vinyard1 bone dimensions Craniofacial bone dimensions. inbred   (21) both 6-8wks 2009
Vulpe1 mineral quantification Liver mineral levels. Iron, copper, zinc. Iron homeostasis. inbred   (18) both 8wks 2010
Vulpe1 transferrin quantification Diferric transferrin (plasma). inbred   (18) both 8wks 2010
Wahlsten1 elevated plus maze Locomotor, exploratory, and anxiety-related behavior. inbred   (21) both 9, 12 wks 2003
Wahlsten1 histopathology Corpus callosum, hippocampus, anterior commisure. inbred   (21) both 9, 12 wks 2003
Wahlsten1 open field test Locomotor, exploratory, and anxiety-related behavior. 5 min test. inbred   (21) both 9, 12 wks 2003
Wahlsten1 organ weights Brain weight. inbred   (21) both 9, 12 wks 2003
Wahlsten2 behavior observation Wildness scoring during various phenotyping tests. inbred   (21) both 10-12wks 2003
Willott1 acoustic startle test Acoustic startle response, prepulse inhibition. inbred w/CC7   (40) both 5-6wks 2002
Willott1 body weight Body weight inbred w/CC7   (40) both 5-6wks 2002
Wiltshire1 elevated plus maze Locomotor activity. inbred   (38) both 12-14wks 2010
Wiltshire1 light-dark box Light-dark test. Anxiety-related behavior. inbred   (38) both 12-14wks 2010
Wiltshire1 open field test Locomotor activity. inbred   (38) both 12-14wks 2010
Wiltshire2 drug and metabolite quantification
with fluoxetine 		Fluoxetine and norfluoxetine concentration (serum) after fluoxetine. inbred   (30) m 9-11wks 2011
Wiltshire2 open field test
with fluoxetine 		Locomotor activity, exploratory and anxiety-related behavior. Fluoxetine-treated vs. control. 7 min test. inbred   (30) m 9-11wks 2011
Wiltshire2 tail suspension test
with fluoxetine 		Immobility. Fluoxetine-treated vs. control. 5 min test. inbred   (30) m 9-11wks 2011
Wiltshire3 biomarker quantification
with fluoxetine 		Brain tissue survey of 30 biochemical analytes. Fluoxetine-treated vs. control. 21d. inbred   (30) m 10-11wks 2011
Wiltshire4 immune cell quantification
with BEZ235, doxorubicin, idarubicin, selumetinib 		In vitro study of 4 cancer chemotherapies (BEZ235, doxorubicin, idarubicin, selumetinib) vs. control. Effect on immune cells. Normalized data. inbred w/CC7   (36) m 10wks 2015
Xing1 ECG Heart rate and wave intervals. Conscious. Aging study, 6mo, 12mo, 20mo. inbred   (29) both 26, 52, 87 wks 2008
Xing2 gait analysis Aging study, 6mo, 12mo, 18mo. inbred   (31) both 26, 52, 78 wks 2010
Yuan1 body weight Aging study, 6mo, 12mo, and 18mo. inbred   (33) both 26, 52, 78 wks 2007
Yuan1 hormone quantification Insulin-like growth factor 1 (serum). Aging study, 6mo, 12mo, and 18mo. inbred   (33) both 26, 52, 78 wks 2007
Yuan2 colony observation Life span study. Survival curves. Aging study. inbred   (31) both max lifespan 2007
Yuan3 lipid profile Cholesterol (HDL). Aging study, 6mo, 12mo, 18mo. 4h fast, plasma. inbred   (32) both 26, 52, 78 wks 2008
Yuan3 metabolic panel Clinical blood chemistry. Aging study, 6mo, 12mo, 18mo. inbred   (32) both 26, 52, 78 wks 2008
Yuan4 colony observation Observed age at vaginal opening (patency). Aging study. inbred   (33) f 2-9wks 2009
Zheng1 tympanometry Middle ear function. inbred   (61) both 15-51d 2008
Zimmermann1 body weight inbred   (30) both 7-15 wks 2020
Zimmermann1 intake monitoring Food and water intake; 2-day test, second day data analyzed during 12:12h light and dark periods. inbred   (30) both 7-15 wks 2020
Zimmermann1 monitoring system Voluntary activity and energy expenditure. 2-day test, second day data analyzed during 12:12h light and dark periods. inbred   (30) both 7-15 wks 2020